Latest from Rutgers Cancer Institute of New Jersey

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer. 
Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.
Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.
Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as recognized by the National Cancer Institute, has been awarded a $15.1 million grant as part of its successful 2019 redesignation. 
Recently approved therapy is administered through program at New Jersey’s Only National Cancer Institute-designated Comprehensive Cancer Center.
Rutgers Cancer Institute investigator was awarded a grant to identify new treatment approaches in non–small cell lung cancer.
Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.
Publication Bottom Border
Border Publication